Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and NovoCure (NVCR)
Sellas Reports Positive Phase 2 Data From AML Study, Files for Patent
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in R/r AML Achieving a 100% Response Rate in Patients With ASXL1 Mutation At the Optimal Dose Level
- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential – - 100% Overall Response Rate in Patients
SELLAS Life Sciences Announces Recommendation Of Independent Data Monitoring Committee Following Completion Of Enrollment In REGAL Phase 3 Study
– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Patients Treatment and Follow-Up Without Any Modificat
SELLAS Life Sciences Gr Q4 EPS $(0.25) Misses $(0.21) Estimate
SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 41.86 percent increase over losse
SELLAS Life Sciences GAAP EPS of -$1.34 Misses by $0.24
Sellas Life Sciences Group Files For Mixed Shelf Offering Of Up To $200M
Sellas Life Sciences Group Files For Mixed Shelf Offering Of Up To $200M
SELLAS Life Sciences 2023 R&D Expenses $24M >SLS
SELLAS Life Sciences 2023 R&D Expenses $24M >SLS
Press Release: SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update -- Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal
Buy Rating for SELLAS Life Sciences Amid Positive AML Study Results and Strengthened Financials
SELLAS Announces Topline Data From Phase 2a Study of SLS009 In Relapsed/Refractory Acute Myeloid Leukemia And Provides Steering Committee Update on Phase 3 REGAL Study
Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April -Phase 2a study of SLS009 in r/r AML: 50% Response Rate i
Press Release: SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules NEW YORK, March 19, 2024 (GLOBE NEWSWIR
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Dow Falls Over 200 Points; Adobe Shares Plunge
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points on Friday. The Dow traded down 0.55% to 38,692.43 while the NASDAQ fell 0.90% to 15,982.65. The S&P
Top Midday Decliners
C3is (CISS) said Friday it priced a firm commitment underwritten public offering of 120 million units, with gross proceeds of about $6 million. Net proceeds will be used for capital expenditures, incl
VERI, STI and VERB Among Mid-day Movers
Crude Oil Edges Lower; US Consumer Sentiment Falls In March
U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points on Friday. The Dow traded down 0.37% to 38,761.74 while the NASDAQ fell 0.95% to 15,974.83. The S&P 50
Sellas Life Sciences Launches $20 Million Direct Offering, Private Placement -- Shares Fall
Sellas Life Sciences (SLS) said Friday it has signed agreements with two investors for the purchase and sale of about 13 million shares in a direct offering and warrants to buy up to the same number o
SELLAS Life Sciences Secures $20 Million in Stock and Warrant Offering
Geron, Graphite Bio, Immuneering Among Healthcare Movers
No Data